Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Share-based Compensation: 2019-2023

Historic Share-based Compensation for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2023 value amounting to $2.2 million.

  • ADC Therapeutics' Share-based Compensation fell 95.50% to $2.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $13.5 million, marking a year-over-year decrease of 72.64%. This contributed to the annual value of $6.6 million for FY2024, which is 51.33% down from last year.
  • According to the latest figures from Q4 2023, ADC Therapeutics' Share-based Compensation is $2.2 million, which was up 6.58% from $2.1 million recorded in Q3 2023.
  • In the past 5 years, ADC Therapeutics' Share-based Compensation ranged from a high of $60.4 million in Q4 2021 and a low of $216 during Q3 2019.
  • Moreover, its 3-year median value for Share-based Compensation was $568,134 (2021), whereas its average is $10.3 million.
  • In the last 5 years, ADC Therapeutics' Share-based Compensation slumped by 99.63% in 2021 and then spiked by 60,162.73% in 2023.
  • Over the past 5 years, ADC Therapeutics' Share-based Compensation (Quarterly) stood at $1.1 million in 2019, then reached $3.8 million in 2020, then slumped by 99.63% to $60.4 million in 2021, then decreased by 18.45% to $49.3 million in 2022, then tumbled by 95.50% to $2.2 million in 2023.
  • Its Share-based Compensation was $2.2 million in Q4 2023, compared to $2.1 million in Q3 2023 and $1.1 million in Q2 2023.